tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2023 Jan 11;115:109650.
doi: 10.1016/j.intimp.2022.109650. Online ahead of print.
A perspective on SARS-CoV-2 virus-like particles vaccines
Xiaoyang Gao[SUP] 1 [/SUP], Yeting Xia[SUP] 2 [/SUP], Xiaofang Liu[SUP] 3 [/SUP], Yinlan Xu[SUP] 4 [/SUP], Pengyang Lu[SUP] 2 [/SUP], Zhipeng Dong[SUP] 2 [/SUP], Jing Liu[SUP] 5 [/SUP], Gaofeng Liang[SUP] 6 [/SUP]
Affiliations
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first appeared in Wuhan, China, in December 2019. The 2019 coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, has spread to almost all corners of the world at an alarming rate. Vaccination is important for the prevention and control of the COVID-19 pandemic. Efforts are underway worldwide to develop an effective vaccine against COVID-19 using both traditional and innovative vaccine strategies. Compared to other vaccine platforms, SARS-CoV-2 virus-like particles （VLPs ）vaccines, as a new vaccine platform, have unique advantages: they have artificial nanostructures similar to natural SARS-CoV-2, which can stimulate good cellular and humoral immune responses in the organism; they have no viral nucleic acids, have good safety and thermal stability, and can be mass-produced and stored; their surfaces can be processed and modified, such as the adjuvant addition, etc.; they can be considered as an ideal platform for COVID-19 vaccine development. This review aims to shed light on the current knowledge and progress of VLPs vaccines against COVID-19, especially those undergoing clinical trials.
Keywords: COVID-19; SARS-CoV-2; VLPs; Vaccines.
. 2023 Jan 11;115:109650.
doi: 10.1016/j.intimp.2022.109650. Online ahead of print.
A perspective on SARS-CoV-2 virus-like particles vaccines
Xiaoyang Gao[SUP] 1 [/SUP], Yeting Xia[SUP] 2 [/SUP], Xiaofang Liu[SUP] 3 [/SUP], Yinlan Xu[SUP] 4 [/SUP], Pengyang Lu[SUP] 2 [/SUP], Zhipeng Dong[SUP] 2 [/SUP], Jing Liu[SUP] 5 [/SUP], Gaofeng Liang[SUP] 6 [/SUP]
Affiliations
- PMID: 36649673
- DOI: 10.1016/j.intimp.2022.109650
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first appeared in Wuhan, China, in December 2019. The 2019 coronavirus disease (COVID-19) pandemic, caused by SARS-CoV-2, has spread to almost all corners of the world at an alarming rate. Vaccination is important for the prevention and control of the COVID-19 pandemic. Efforts are underway worldwide to develop an effective vaccine against COVID-19 using both traditional and innovative vaccine strategies. Compared to other vaccine platforms, SARS-CoV-2 virus-like particles （VLPs ）vaccines, as a new vaccine platform, have unique advantages: they have artificial nanostructures similar to natural SARS-CoV-2, which can stimulate good cellular and humoral immune responses in the organism; they have no viral nucleic acids, have good safety and thermal stability, and can be mass-produced and stored; their surfaces can be processed and modified, such as the adjuvant addition, etc.; they can be considered as an ideal platform for COVID-19 vaccine development. This review aims to shed light on the current knowledge and progress of VLPs vaccines against COVID-19, especially those undergoing clinical trials.
Keywords: COVID-19; SARS-CoV-2; VLPs; Vaccines.